



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

McMMAF

Cat. No.:	HY-15578
CAS No.:	863971-19-1
Molecular Formula:	C ₄₉ H ₇₆ N ₆ O ₁₁
Molecular Weight:	925.16
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-20°C, stored under nitrogen

* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (108.09 mM)					
	* "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.0809 mL	5.4045 mL	10.8089 mL
5 mM			0.2162 mL	1.0809 mL	2.1618 mL	
10 mM		0.1081 mL	0.5404 mL	1.0809 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (5.40 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (5.40 mM); Clear solution 3. Add each solvent one by one: 1% DMSO >> 99% saline Solubility: ≥ 0.5 mg/mL (0.54 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent ^{[1][2]} .
IC₅₀ & Target	Auristatin

CUSTOMER VALIDATION

- J Control Release. 2020 Nov 10;327:186-197.
- Anal Chem. 2022 Feb 1.
- Patent. US10087260B2.
- Patent. US20160304621A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69(6):2358-2364.
- [2]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA